000130949 001__ 130949
000130949 005__ 20240228143504.0
000130949 0247_ $$2doi$$a10.1186/s12885-016-2561-1
000130949 0247_ $$2pmid$$apmid:27430336
000130949 0247_ $$2pmc$$apmc:PMC4949758
000130949 0247_ $$2altmetric$$aaltmetric:9911280
000130949 037__ $$aDKFZ-2017-06025
000130949 041__ $$aeng
000130949 082__ $$a610
000130949 1001_ $$00000-0002-5971-5436$$aWiskemann, Joachim$$b0$$eFirst author
000130949 245__ $$aPOSITIVE study: physical exercise program in non-operable lung cancer patients undergoing palliative treatment.
000130949 260__ $$aLondon$$bBioMed Central$$c2016
000130949 3367_ $$2DRIVER$$aarticle
000130949 3367_ $$2DataCite$$aOutput Types/Journal article
000130949 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524485061_2921
000130949 3367_ $$2BibTeX$$aARTICLE
000130949 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130949 3367_ $$00$$2EndNote$$aJournal Article
000130949 520__ $$aPatients with advanced stage non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) often experience multidimensional impairments, affecting quality of life during their course of disease. In lung cancer patients with operable disease, several studies have shown that exercise has a positive impact on quality of life and physical functioning. There is limited evidence regarding efficacy for advanced lung cancer patients undergoing palliative treatment. Therefore, the POSITIVE study aims to evaluate the benefit of a 24-week exercise intervention during palliative treatment in a randomized controlled setting.The POSITIVE study is a randomized, controlled trial investigating the effects of a 24-week exercise intervention during palliative treatment on quality of life, physical performance and immune function in advanced, non-operable lung cancer patients. 250 patients will be recruited in the Clinic for Thoracic Diseases in Heidelberg, enrolment begun in November 2013. Main inclusion criterion is histologically confirmed NSCLC (stage IIIa, IIIb, IV) or SCLC (Limited Disease-SCLC, Extensive Disease-SCLC) not amenable to surgery. Patients are randomized into two groups. Both groups receive weekly care management phone calls (CMPCs) with the goal to assess symptoms and side effects. Additionally, one group receives a combined resistance and endurance training (3x/week). Primary endpoints are quality of life assessed by the Functional Assessment of Cancer Therapy for patients with lung cancer (FACT-L, subcategory Physical Well-Being) and General Fatigue measured by the Multidimensional Fatigue Inventory (MFI-20). Secondary endpoints are physical performance (maximal voluntary isometric contraction, 6-min walk distance), psychosocial (depression and anxiety) and immunological parameters and overall survival.The aim of the POSITIVE trial is the evaluation of effects of a 24-week structured and guided exercise intervention during palliative treatment stages. Analysis of various outcomes (such as quality of life, physical performance, self-efficacy, psychosocial and immunological parameters) will contribute to a better understanding of the potential of exercise in advanced lung cancer patients. In contrast to other studies with advanced oncological patients the POSITIVE trial provides weekly phone calls to support patients both in the intervention and control group and to segregate the impact of physical activity on quality of life.ClinicalTrials.gov NCT02055508 (Date: December 12, 2013).
000130949 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000130949 588__ $$aDataset connected to CrossRef, PubMed,
000130949 7001_ $$aHummler, Simone$$b1
000130949 7001_ $$0P:(DE-HGF)0$$aDiepold, Christina$$b2
000130949 7001_ $$0P:(DE-He78)1f4e474ebc02bd0cf008f2b9098525d2$$aKeil, Melanie$$b3$$udkfz
000130949 7001_ $$0P:(DE-He78)a6cd39ee5b1d8276f6bc716b3f7881b7$$aAbel, Ulrich$$b4$$udkfz
000130949 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b5$$udkfz
000130949 7001_ $$0P:(DE-He78)1732377f6242a18280bc6aaa196988d1$$aBeckhove, Philipp$$b6$$udkfz
000130949 7001_ $$aUlrich, Cornelia M$$b7
000130949 7001_ $$aSteins, Martin$$b8
000130949 7001_ $$aThomas, Michael$$b9
000130949 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-016-2561-1$$gVol. 16, no. 1, p. 499$$n1$$p499$$tBMC cancer$$v16$$x1471-2407$$y2016
000130949 909CO $$ooai:inrepo02.dkfz.de:130949$$pVDB
000130949 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-5971-5436$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130949 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000130949 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1f4e474ebc02bd0cf008f2b9098525d2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000130949 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a6cd39ee5b1d8276f6bc716b3f7881b7$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000130949 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000130949 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1732377f6242a18280bc6aaa196988d1$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000130949 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000130949 9141_ $$y2016
000130949 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2015
000130949 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130949 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130949 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130949 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000130949 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000130949 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000130949 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130949 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130949 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130949 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130949 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130949 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000130949 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000130949 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000130949 9201_ $$0I:(DE-He78)G040-20160331$$kG040$$lKlinische Studienzentrale$$x1
000130949 9201_ $$0I:(DE-He78)D015-20160331$$kD015$$lTranslationale Immunologie$$x2
000130949 9201_ $$0I:(DE-He78)G808-20160331$$kG808$$lIMT IM Platform$$x3
000130949 980__ $$ajournal
000130949 980__ $$aVDB
000130949 980__ $$aI:(DE-He78)G210-20160331
000130949 980__ $$aI:(DE-He78)G040-20160331
000130949 980__ $$aI:(DE-He78)D015-20160331
000130949 980__ $$aI:(DE-He78)G808-20160331
000130949 980__ $$aUNRESTRICTED